protocolSection identificationModule nctId: NCT06381154, orgStudyIdInfo id: MC230404, secondaryIdInfos id: NCI-2024-03078, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 23-009036, type: OTHER, domain: Mayo Clinic Institutional Review Board, secondaryIdInfos id: MC230404, type: OTHER, domain: Mayo Clinic, secondaryIdInfos id: P01CA084203, type: NIH, link: https://reporter.nih.gov/quickSearch/P01CA084203, secondaryIdInfos id: P30CA015083, type: NIH, link: https://reporter.nih.gov/quickSearch/P30CA015083, briefTitle: Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-05, primaryCompletionDateStruct date: 2029-07-04, completionDateStruct date: 2029-07-04, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, collaborators name: National Cancer Institute (NCI), descriptionModule briefSummary: This phase II trial tests how well photoradiation with verteporfin and pembrolizumab plus standard of care chemotherapy works in treating patients with pancreatic cancer that cannot be removed by surgery (unresectable), that has spread to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). Photoradiation uses light activated drugs, such as verteporfin, that become active when exposed to light. These activated drugs may kill tumor cells. Vertoporfin may also increase tumor response to immunotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX), work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Photoradiation with verteporfin and pembrolizumab plus standard of care chemotherapy may kill more tumor cells in patients with unresectable, locally advanced or metastatic pancreatic cancer., conditionsModule conditions: Locally Advanced Pancreatic Adenocarcinoma, conditions: Metastatic Pancreatic Adenocarcinoma, conditions: Stage II Pancreatic Cancer AJCC v8, conditions: Stage III Pancreatic Cancer AJCC v8, conditions: Stage IV Pancreatic Cancer AJCC v8, conditions: Unresectable Pancreatic Adenocarcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Biopsy, interventions name: Biospecimen Collection, interventions name: Computed Tomography, interventions name: Endoscopic Ultrasound, interventions name: Fluorouracil, interventions name: Irinotecan, interventions name: Leucovorin, interventions name: Lymph Node Biopsy, interventions name: Magnetic Resonance Imaging, interventions name: Oxaliplatin, interventions name: Pembrolizumab, interventions name: Photodynamic Therapy, interventions name: Positron Emission Tomography, interventions name: Questionnaire Administration, interventions name: Verteporfin, outcomesModule primaryOutcomes measure: Overall response rate (ORR), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Incidence of adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Vinay Chandrasekhara, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False